These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 22203733)

  • 1. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
    Montano R; Chung I; Garner KM; Parry D; Eastman A
    Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
    Walton MI; Eve PD; Hayes A; Valenti M; De Haven Brandon A; Box G; Boxall KJ; Aherne GW; Eccles SA; Raynaud FI; Williams DH; Reader JC; Collins I; Garrett MD
    Mol Cancer Ther; 2010 Jan; 9(1):89-100. PubMed ID: 20053762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
    Guzi TJ; Paruch K; Dwyer MP; Labroli M; Shanahan F; Davis N; Taricani L; Wiswell D; Seghezzi W; Penaflor E; Bhagwat B; Wang W; Gu D; Hsieh Y; Lee S; Liu M; Parry D
    Mol Cancer Ther; 2011 Apr; 10(4):591-602. PubMed ID: 21321066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
    Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
    Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation.
    Samadder P; Suchánková T; Hylse O; Khirsariya P; Nikulenkov F; Drápela S; Straková N; Vaňhara P; Vašíčková K; Kolářová H; Binó L; Bittová M; Ovesná P; Kollár P; Fedr R; Ešner M; Jaroš J; Hampl A; Krejčí L; Paruch K; Souček K
    Mol Cancer Ther; 2017 Sep; 16(9):1831-1842. PubMed ID: 28619751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
    Levesque AA; Fanous AA; Poh A; Eastman A
    Mol Cancer Ther; 2008 Feb; 7(2):252-62. PubMed ID: 18281511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.
    Montano R; Thompson R; Chung I; Hou H; Khan N; Eastman A
    BMC Cancer; 2013 Dec; 13():604. PubMed ID: 24359526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
    Zemanova J; Hylse O; Collakova J; Vesely P; Oltova A; Borsky M; Zaprazna K; Kasparkova M; Janovska P; Verner J; Kohoutek J; Dzimkova M; Bryja V; Jaskova Z; Brychtova Y; Paruch K; Trbusek M
    Oncotarget; 2016 Sep; 7(38):62091-62106. PubMed ID: 27556692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
    Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
    Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
    King C; Diaz H; Barnard D; Barda D; Clawson D; Blosser W; Cox K; Guo S; Marshall M
    Invest New Drugs; 2014 Apr; 32(2):213-26. PubMed ID: 24114124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01.
    Eastman A; Kohn EA; Brown MK; Rathman J; Livingstone M; Blank DH; Gribble GW
    Mol Cancer Ther; 2002 Oct; 1(12):1067-78. PubMed ID: 12481430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
    Blackwood E; Epler J; Yen I; Flagella M; O'Brien T; Evangelista M; Schmidt S; Xiao Y; Choi J; Kowanetz K; Ramiscal J; Wong K; Jakubiak D; Yee S; Cain G; Gazzard L; Williams K; Halladay J; Jackson PK; Malek S
    Mol Cancer Ther; 2013 Oct; 12(10):1968-80. PubMed ID: 23873850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells.
    Herůdková J; Paruch K; Khirsariya P; Souček K; Krkoška M; Vondálová Blanářová O; Sova P; Kozubík A; Hyršlová Vaculová A
    Neoplasia; 2017 Oct; 19(10):830-841. PubMed ID: 28888100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
    Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
    Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
    Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
    Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
    Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.
    Warren NJH; Eastman A
    J Biol Chem; 2019 Feb; 294(6):1763-1778. PubMed ID: 30573684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
    Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
    Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
    Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
    Sakurikar N; Thompson R; Montano R; Eastman A
    Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.